Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | NQO2 | P16083 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22728641 | 1.00 | MAPT (0.37) | MAPTNQO2ALDH1A1GAAKDM4E | |
| SCHEMBL31355218 | 0.92 | MAPT (0.43) | MAPTNQO2ALDH1A1GAAKDM4E | |
| SCHEMBL3174167 | 0.92 | MAPT (0.43) | MAPTNQO2ALDH1A1GAAKDM4E | |
| SCHEMBL29364593 | 0.92 | MAPT (0.43) | MAPTNQO2ALDH1A1GAAKDM4E | |
| SCHEMBL29576079 | 0.92 | MAPT (0.43) | MAPTNQO2ALDH1A1GAAKDM4E | |
| SCHEMBL12520346 | 0.92 | MAPT (0.43) | MAPTNQO2ALDH1A1GAAKDM4E | |
| SCHEMBL18958854 | 0.92 | MAPT (0.43) | MAPTNQO2ALDH1A1GAAKDM4E | |
| SCHEMBL1988460 | 0.92 | MAPT (0.43) | MAPTNQO2ALDH1A1GAAKDM4E | |
| SCHEMBL2559367 | 0.92 | MAPT (0.43) | MAPTNQO2ALDH1A1GAAKDM4E | |
| SCHEMBL3224612 | 0.90 | MAPT (0.42) | MAPTNQO2ALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084835-B2 | 2,3-bisphosphinopyrazine derivative, method for producing same, transition metal complex, asymmetric catalyst, and method for producing organic boron compound | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-08-10 | — | — | US | disclosed |
| US-11053265-B2 | Optically active substituted 2,3-bisphosphinoquinoxalines and processes for producing the same | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-07-06 | — | — | US | disclosed |
| US-20210047351-A1 | 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-02-18 | — | — | US | disclosed |
| US-20200377536-A1 | OPTICALLY ACTIVE 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377536-A1 | OPTICALLY ACTIVE 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | ORC3, BMP2, TERT | MAPT 4211/4885NQO2 3706/4885ALDH1A1 3411/4885 |
| US-20210047351-A1 | 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | BPGM, COASY, BRSK2 | MAPT 4514/4885NQO2 3601/4885ALDH1A1 3485/4885 |
| US-11084835-B2 | 2,3-bisphosphinopyrazine derivative, method for producing same, transition metal complex, asymmetric catalyst, and method for producing organic boron compound | BPGM, BRSK2, COASY | MAPT 4508/4885NQO2 3527/4885ALDH1A1 3387/4885 |
| US-11053265-B2 | Optically active substituted 2,3-bisphosphinoquinoxalines and processes for producing the same | TBXA2R, TBC1D15, P2RY2 | MAPT 4790/4885NQO2 1596/4885ALDH1A1 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.